ArticleOncoimmunology2021

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.

Craig L Slingluff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.